Download Yen-Shen Lu

Dr. Yen-Shen Lu
Clinical Associate Professor, Department of Internal Medicine, National
Taiwan University College of Medicine, Taiwan
Dr. Lu graduated from the Chinese Medical College of Medicine in 1992. He
completed his postgraduate training in 2006 at the Institute of Clinical
Medicine, National Taiwan University College of Medicine, Taiwan, and has
been appointed as an Attending Doctor at the Department of Oncology,
National Taiwan University Hospital since 1999. During 2005 to 2006, Dr. Lu
had been a clinical fellow and post-doctoral researcher at the College of
Pharmacy and Comprehensive Cancer Center at Ohio State University, USA.
Dr. Lu is a member of various societies, including Taiwan Society of Internal
Medicine, American Association of Cancer Research (AACR), and the Breast
Cancer Society of Taiwan. He was awarded scholarship in Training Award of
92th Annual Meeting of AACR in 2001. He is now appointed Clinical Associate
Professor at the Department of Internal Medicine at the National Taiwan
University College of Medicine.
Dr. Lu is an invited speaker in different international conferences, such as the
Asia Oncology Summit and Global Breast Cancer Conference. He is a
initiator, protocol writer, principal investigator and co-principal investigator for
various clinical trials over the years. He has written over 30 conference
papers and published over 60 journals in different international peer-reviewed
journals, including Lancet Oncology and Cancer Research. Dr. Lu is also the
co-author in a book chapter entitled ‘Histone Deacetylase Inhibitors in Cancer
Therapy’.
CURRICULUM VIATE
Yen - Shen Lu, MD., PhD.
盧彥伸醫師
PERSONAL：
Address:
Department of Oncology
National Taiwan University Hospital
#7 Chung-Shan South Road,
Taipei, Taiwan, 100
Tel：886-2-23123456 ext 7009
Fax：886-2-23711174
e-mail：[email protected]
Date of Birth: Nov 11, 1966
Place of Birth: Taipei, Taiwan
Marital Status: Married
EDUCATION：
M.D.
Chinese Medical College of Medicine 1985-1992
Ph.D.
Institute of Clinical Medicine, National Taiwan University College of
Medicine 1998-2006
PROFESSIONAL TRAINING：
1991-1992
Internship：National Taiwan University College of Medicine
1993-1996
Residency：Department of Medicine, National Taiwan University
Hospital
1996-1997
Chief Residency：Department of Oncology, National Taiwan
University Hospital
1997-1999
Fellowship, Department of Oncology, National Taiwan University
Hospital
2005-2006
Clinical fellow and Postdoctoral researcher, College of pharmacy,
and Comprehensive Cancer Center, Ohio State University
HOSPITAL APPOINTMENTS：
1999-2001
Attending doctor, Department of Oncology, En Chu Kong Hospital
2001-present Attending doctor, Department of Oncology, National Taiwan
University Hospital
ACADEMIC APPOINTMENTS：
2007-2008
Adjunct Associate Professor, Department of Internal Medicine,
National Taiwan University College of Medicine
2008-present
Clinical Associate Professor, Department of Internal Medicine,
National Taiwan University College of Medicine
LICENSURE and CENTIFICATION：
Chinese Medical License
#021928（1992）
Chinese Board of Internal Medicine #004509（1997）
Chinese Board of Medical Oncology #870003 (1998 )
Chinese Board of Mammary Medicine #0415 ( 2006 )
MEMBERSHIPS：
Taiwan Society of Internal Medicine
1996 – Present
The Chinese Oncology Society
1998 – Present
The Breast Cancer Society of Taiwan
2004 - Present
American Association of Cancer Research
2001-Present
Awards:
Scholar in Training Award of 92th Annual Meeting of AACR in 2001.
SCI PUBLICATIONS：
1. Po-Han Lin; Chang-Fang Chiu; Yen-Shen Lu. Cisplatin as an active
treatment in zoledronate-refractory hypercalcemia. Ann Oncol. 2011 Apr 2
[Epub ahead of print] PMID:21460375
2. Lack of compensatory pAKT activation and eIF4E phosphorylation of
lymphoma cells towards mTOR inhibitor, RAD001. Kuo SH, Hsu CH, Chen
LT, Lu YS, Lin CH, Yeh PY, Jeng HJ, Gao M, Yeh KH, Cheng AL Eur J
Cancer. 2011 Feb 17.
3. The Association of Infrared Imaging Findings of the Breast with Hormone
Receptor and Human Epidermal Growth Factor Receptor 2 Status of
Breast Cancer. Wang J, Shih TT, Yen RF, Lu YS, Chen CY, Mao TL, Lin
CH, Kuo WH, Tsai YS, Chang KJ, Chien KL. Acad Radiol. 2010 Dec 1
4. Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant
chemotherapy for locally advanced breast cancer Yen-Shen Lu, Dar-Ren
Chen, Ling-Min Tseng, Dah-Cherng Yeh, Shou-Tung Chen, Chia-Ming
Hsieh, Hwei-Chung Wang, Hsien-Tang Yeh, Sung-Hsin Kuo, Chiun-Sheng
Huang. Cancer Chemotherapy and Pharmacology. 2010 In press
5. Combinations of mTORC1 inhibitor RAD001 with gemcitabine and
paclitaxel for treating non-Hodgkin lymphoma Chun-Te Chiang, Pei-Yen
Yeh, Ming Gao, Chun-Wei Chen, Ling-Chun Yeh, Wen-Chi Feng,
Sung-Hsin Kuo, Chih-Hung Hsu, Yen-Shen Lu* and Ann-Lii Cheng,
Cancer Letter, 2010, 2010 Dec 8;298(2):195-203. (*corresponding author)
6. The prevalence and assessment of ErbB2-positive breast cancer in Asia:
A literature survey. Yew Oo Tan, Sehwan Han, Yen-Shen Lu, Cheng-Har
Yip, Patrapim Sunpaweravong, Joon Jeong, Priscilla B. Caguioa, Shyam
Aggarwal, Ee Min Yeoh, BSc, and Hanlim Moon. Cancer, 2010 Dec
1;116(23):5348-57.
7. Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and
leucovorin as effective palliative chemotherapy for breast cancer patients
with acute disseminated intravascular coagulation, Po-Han Lin, Yen-Shen
Lu, Ching-Hung Lin, Dwan-Ying Chang, Chiun-Shen Huang, Ann-Lii
Cheng,Kun-Huei Yeh Anticancer Research 2010 Jul;30(7):3087-91.
8. Management of ErbB2-positive breast cancer – insights from preclinical
and clinical studies with lapatinib, Charles Vogel, Arlene Chan, Brunilde
Gril, Sung-Bae Kim, Junichi Kurebayashi, Li Liu, Yen-Shen Lu, Hanlim
Moon Jap. J Clin. Oncol. 2010 Nov;40(11):999-1013
9. Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast
Cancer Patients Treated with Paclitaxel and Cisplatin. Shao YY, Kuo KT,
Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ,
Lin CH, Cheng AL. Jpn J Clin Oncol. 2010 Apr;40(4):286-93
10.Unique features of breast cancer in Asian women-Breast cancer in Taiwan
as an example. Huang CS, Lin CH, Lu YS, Shen CY. J Steroid Biochem
Mol Biol. 2010 Feb 28;118(4-5):300-3..
11.Fractionated evaluation of immunohistochemical hormone receptor
expression enhances prognostic prediction in breast cancer patients
treated with tamoxifen as adjuvant therapy. Lin CH, Lien HC, Hu FC, Lu
YS, Kuo SH, Wu LC, You SL, Cheng AL, Chang KJ, Huang CS. J Zhejiang
Univ Sci B. 2010 Jan;11(1):1-9.
12.Management of HER2-positive breast cancer in Asia: consensus
statement from the Asian Oncology Summit. Nan Soon Wong, Benjamin O
Anderson, Kei Siong Khoo, Peng Tiam Ang, Cheng Har Yip,Yen-Shen Lu,
Narind Voravud, Zhi-Ming Shao, Kathleen I Pritchard. Lancet Oncol.
2009 Nov;10(11):1077-85.
13.O(6)-Methylguanine-DNA methyltransferase expression and prognostic
value in brain metastases of lung cancers. Wu PF, Kuo KT, Kuo LT, Lin
YT, Lee WC, Lu YS, Yang CH, Wu RM, Tu YK, Tasi JC, Tseng HM, Tseng
SH, Cheng AL, Lin CH. Lung Cancer. 2009 Sep 7
14.Locoregional Therapy Improves Survival for Metastatic Breast Cancer
Patients? Benefit Remains Questionable! Chang DY, Lin CH, Lu YS.
J Clin Oncol. 2009 Nov 1;27(31):e179;
15.Induction of Bim Expression Contributes to the Antitumor Synergy
Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular
Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular
Carcinoma. Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang
DS, Lu YS, Hsu C, Cheng AL.
Clin Cancer Res. 2009 Sep 8.
15(18):5820-8.
16.Molecular Subtypes of Breast Cancer Emerging in Young Women in
Taiwan: Evidence for More than Just Westernization as a Reason for the
Disease in Asia Ching-Hung Lin, Jau-Yu Liau, Yen-Shen Lu, Chiun-Sheng
Huang, Wei-Chung Lee, Kuan-Ting Kuo, Ying-Chun Shen, Sung-Hsin Kuo,
Chieh Lan, Jacqueline Ming Liu, Wun-Hon Kuo, King-Jen Chang, and
Ann-Lii Cheng,
Cancer Epidemiology, Biomarkers & Prevention. 2009
Jun;18(6):1807-14.
17.Bortezomib overcomes TRAIL resistance in hepatocellular carcinoma cells
in part through the inhibition of PI3K/Akt pathway Kuen-Feng Chen,
Pei-Yen Yeh, Chiun Hsu , Chih-Hung Hsu, Yen-Shen Lu, Hsing-Pang
Hsieh, Pei-Jer Chen, Ann-Lii Cheng.
J. Biol Chem 2009 April
24;284(17):11121-33.
18. OSU-03012, a novel celecoxib derivative, induces reactive oxygen
species-related autophagy in hepatocellular carcinoma.Gao M, Yeh PY, Lu
YS, Hsu CH, Chen KF, Lee WC, Feng WC, Chen CS, Kuo ML, Cheng AL. .
Cancer Res 2008 Nov 15;68(22):9348-57.
19.NF-kappaB p50 promotes tumor cell invasion through negative regulation
of invasion suppressor gene CRMP-1 in human lung adenocarcinoma
cells. Gao M, Yeh PY, Lu YS, Chang WC, Kuo ML, Cheng AL. Biochem
Biophys Res Commun. 2008 Nov 14;376(2):283-7.
20.Down-regulation of phospho-Akt is a major molecular determinant of
bortezomib-induced apoptosis in hepatocellular carcinoma cells. Chen KF,
Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL Cancer Res. 2008 Aug
15;68(16):6698-707.
21.Dose variation and regimen modification of adjuvant chemotherapy in daily
practice affect survival of stage I-II and operable stage III Taiwanese
breast cancer patients. Kuo SH, Lien HC, You SL, Lu YS, Lin CH, Chen
TZ, Huang CS, Breast. 2008 Dec;17(6):646-53. Epub 2008 Jul 1
22.The CYP19 TTTA Repeat Polymorphism Is Related to the Prognosis of
Premenopausal Stage I-II and Operable Stage III Breast Cancers, Huang
CS, Kuo SH, Lien HC, Yang SY, You SL, Shen CY, Lin CH, Lu YS, Chang
KJ. Oncologist. 2008;13:751-60.
23.Differential expression of glucocorticoid receptor in carcinomas of the
human digestive system, H-C Lien, Y-S Lu, C-T Shun, Y-T Yao, W-C
Chang1 & A-L Cheng Histopathology 2008 Feb;46(4):1119-30
24.FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through
Activation of Protein Kinase C Delta Signaling. Jui-Hsiang Hung,
Yen-Shen Lu, Yu-Chieh Wang, Yi-Hui Ma, Da-Sheng Wang, Samuel K.
Kulp, Natarajan Muthusamy, John C Byrd, Ann-Lii Cheng, and Ching-Shih
Chen Cancer Research, 68:1204-1212, 2008.
25.Efficacy of OSU-HDAC42, a Novel Histone Deacetylase Inhibitor, in
Murine Models of Hepatocellular Carcinoma Yen-Shen Lu, Yoko Kashida,
Samuel K. Kulp, Yu-Chieh Wang, Jui-Hsiang Hung, Monica Tang,
Zhong-Zhe Lin, Te-Jung Chen, Ann-Lii Cheng, and Ching-Shih Chen.
Hepatology, 2007 Oct;46(4):1119-30.
26.Pneumatosis coli after etoposide chemotherapy for breast cancer. Shih IL,
Lu YS, Wang HP, Liu KL. J Clin Oncol. 2007 Apr 20;25(12):1623-5.
27.Histone deacetylase inhibitors sensitize prostate cancer cells to agents
that produce DNA double-strand breaks by targeting Ku70 acetylation.
Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS,
Matsuyama S, Chen CY, Chen CS. Cancer Res. 2007 Jun
1;67(11):5318-27.
28.A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus
leucovorin in patients with chemotherapy-pretreated metastatic breast
cancer. Lin CC, Cheng AL, Hsu CH, Lu YS, Hsu C, Yeh KH, Wu CY,
Huang CS, Yang CH. Anticancer Res. 2007 ;27(1B):641-5.
29.Differential expression of glucocorticoid receptor in human breast tissues
and related neoplasms. Lien HC, Lu YS, Cheng AL, Chang WC, Jeng YM,
Kuo YH, Huang CS, Chang KJ, Yao YT. J Pathol. 2006 Jul;209(3):317-27.
30.Glucocorticoid receptor expression in advanced non-small cell lung cancer:
clinicopathological correlation and in vitro effect of glucocorticoid on cell
growth and chemosensitivity Lu YS, Lien HC, Yeh PY, Kuo SH, Chang
WC, Kuo ML, Cheng AL. Lung Cancer. 2006 Sep;53(3):303-10.
31.Phase I study of biweekly gemcitabine followed by oxaliplatin and
simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic
cancer. Ch'ang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin
JT, Wang HP, Shiah HS, Liu TW, Chang JY, Whang-Peng J, Chen LT. J
Gastroenterol Hepatol. 2006 May;21(5):874-9.
32.Glucocorticoids enhance cytotoxicity of cisplatin via suppression of
NF-{kappa}B activation in the glucocorticoid receptor-rich human cervical
carcinoma cell line SiHa. Lu YS, Yeh PY, Chuang SE, Gao M, Kuo ML,
Cheng AL. J Endocrinol. 2006 Feb;188(2):311-9.
33.Effects of glucocorticoids on the growth and chemosensitivity of carcinoma
cells are heterogeneous and require high concentration of functional
glucocorticoid receptors. Lu YS, Lien HC, Yeh PY, Yeh KH, Kuo ML, Kuo
SH, Cheng AL. World J Gastroenterol. 2005 Oct 28;11(40):6373-80.
34.Long-term hepatic consequences of chemotherapy-related HBV
reactivation in lymphoma patients. Su WP, Wen CC, Hsiung CA, Su IJ,
Cheng AL, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu C, Hsu CH, Lu
YS, Tien HF, Chao TY, Chen LT, Whang-Peng J, Chen PJ. World J
Gastroenterol. 2005 Sep 14;11(34):5283-8.
35.Phase II Study of Weekly Paclitaxel and 24-Hour Infusion of High-Dose
5-Fluorouracil and Leucovorin in the Treatment of Recurrent or Metastatic
Gastric Cancer. Kun-Huei Yeh, Yen-Shen Lu, Chih-Hung Hsu, Jing-Fang
Lin, Chiun Hsu, Sung-Hsin Kuo, Shiou-Jr Li, Ann-Lii Cheng. Oncology
2005 Oncology. 2005;69(1):88-95.
36.Phase II Study of Weekly Vinorelbine and 24-hour Infusion of High-dose
5-Fluorouracil Plus Leucovorin as First-line Treatment of Advanced Breast
Cancer KH Yeh, YS Lu, CH Hsu, JF Lin, HJ Chao, TC Huang, CY Chung,
CS Chang, CH Yang, AL Cheng British Journal of Cancer . 2005
92:1013-1018
37.Angiogenic response of locally advanced breast cancer to neoadjuvant
chemotherapy evaluated with parametric histogram from dynamic
contrast-enhanced MRI. Yeun-Chung Chang, Chiun-Sheng Huang, Yi-Jui
Liu, Jyh-Horng Chen, Yen-Shen Lu, Wen-Yih I Tseng Phys. Med. Biol. 49
(2004)3593-3602 2004
38.Phase II study of combination doxorubicin, interferon-alpha, and high-dose
tamoxifen treatment for advanced hepatocellular carcinoma. Lu YS. Hsu C.
Li CC. Kuo SH. Yeh KH. Yang CH. Hsu CH. Wu CY. Cheng AL
Hepato-Gastroenterology. 51(57):815-9, 2004
39.Recent advances in the management of primary breast cancers. Lu YS,
Kuo SH, Huang CS J Formos Med Assoc. 103(8):579-98.2004
40.Weekly gemcitabine plus 24-h infusion of high-dose
5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of
the biliary tract. Hsu C. Shen YC. Yang CH. Yeh KH. Lu YS. Hsu CH. Liu
HT. Li CC. Chen JS. Wu CY. Cheng AL British Journal of Cancer.
90(9):1715-9,2004
41.High-dose tamoxifen modulates drug resistance to doxorubicin,
dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma. Yeh KH.
Lu YS. Hsiao CH. Cheng AL. Anticancer Research. 23(6D):5133-7, 2003
42.A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of
high-dose 5-f;uorouracil and leucovorin (MP-HDFL) in patients with
metastatic and recurrent esophageal cancer – improving toxicity profile by
infusional schedule and double biochemical modulation of 5-fluorouracil.
CH Hsu, AL Cheng, C Hsu, CH Yang, YS Lu, CC Lin, CF Bu, KH Yeh.
Anticancer Research. 22: 3621-28, 2002.
43.Phase II trial combining paclitaxel with 24-hour infusion cisplatin for
chemotherapy-naïve patients with locally advanced or metastatic breast
cancer. C, Hsu, CS Huang, TY Chao, YS Lu. CF Bu, MM, Chen, AL
Cheng. Cancer 95(10) 2044-50, 2002.
44.Basal levels and patterns of anticancer drug-induced activation of NF-kB,
and its attenuation by tamoxifen, dexamethasone, and curcumin in
carcinoma cells. S.E. Chung, P.Y. Yeh, Y.S. Lu, G.M. Lai, C.M. Liao, M.
Gao, A.L. Cheng. Biochemical Pharmacology. 63(9):1709-16, 2002.
45.Chen HS. Yen TS. Lu YS. Yang JC. Ko YL. Transient 'milky urine' after
cardiac catheterization: another unreported cause of non-parasitic chyluria
[letter]. Nephron. 72(2):367-8, 1996.
Conference paper：
1. C. Hsu, Y.-C. Shen, C.-H. Yang, K.-H. Yeh, Y.-S. Lu, C.-C. Li, C.-Y. Wu,
A.-L. Cheng Phase II study of weekly gemcitabine plus 24-hour infusion of
high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic
carcinoma of the biliary tract Proc Am Soc Clin Oncol 22: 2003 (abstr
1322)
2. K. H. Yeh, W. Lu, Y. F. Ho, Y. Lu, M. Y. Liu, R. R. Chen, A. L. Cheng A
phase I and pharmacokinetic study of weekly 48-hour infusion of
high-dose 5-fluorouracil and folinic acid in patients with
recurrent/metastatic colorectal cancer 2004 Gastrointestinal Cancer
Synposium abstract 261
3. KH Yeh, YS Lu, CH Hsu, C Hsu, H J Chao, CH Hsiao, SH Kuo, JC Lin, CH
Yang, AL Cheng A phase II study of weekly vinorelbine and 24-hour
infusion of high-dose 5-fluorouracil/leucovorin (VNB-HDFL) in the first-line
treatment of advanced breast cancer Proc Am Soc Clin Oncol 21: 2002
(abstr 2006)
4. K. Yeh, C. Hsu, Y. Lu, C. Hsu, S. Kuo, C. Huang, Y. Shen, C. Hsiao, C.
Yang, A. Cheng. Phase II study of sequential non-cross-resistant
chemotherapy using weekly 24-hour infusion of cisplatin, high-dose
5-fluorouracil and leucovorin (P-HDFL) followed by weekly docetaxel and
irinotecan (DI) for recurrent or metastatic gastric cancer: an interim
analysis Journal of Clinical Oncology, 2006 ASCO Annual Meeting
Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 14063
5. K.-H. Yeh, C.-H. Hsu, J.-F. Lin, Y.-S. Lu, H.-T. Li, C.-L. Huang, C.-H.
Hsiao, A.-L. Cheng. Prolonged survival in a pilot study of sequential
non-cross-resistant chemotherapy using weekly 24-hour infusion of
cisplatin, high-dose 5-fluorouracil and leucovorin (P-HDFL) followed by
weekly docetaxel and irinotecan (DI) for recurrent or metastatic gastric
cancer Proc Am Soc Clin Oncol 22: 2003 (abstr 1229)
6. C.-H. Hsu, K.-H. Yeh, C.-C. Lin, Z.-Z. Lin, C. Hsu, Y.-S. Lu, C.-F. Bu, A.-L.
Cheng. Multi-fractionation of paclitaxel and cisplatin by twice weekly
schedule, plus weekly 24-hour infusion of high-dose 5-fluorouracil and
leucovorin (twice weekly TP-HDFL) in the treatment of metastatic or
recurrent esophageal cancer. Proc Am Soc Clin Oncol 22: 2003 (abstr
1336)
7. Chih-Hung Hsu, Kun-Huei Yeh, Chiun Hsu, Chih-Hsin Yang, Yen-Shen Lu,
Chia-Chi Lin, Ching-Fang Bu, Ann-Lii Cheng. Phase II Clinical Trial of
Methotrexate, Cisplatin, and 24-Hour Infusion of High-Dose 5-Fluororuacil
and Leucovorin (MP-HDFL) for the Treatment of Metastatic or Recurrent
Esophageal Cancer Proc Am Soc Clin Oncol 20: 2001 (abstr 2299)
8. Y. S. Lu, S. H. Kuo, W. P. Su, C. H. Yang, C. Hsu, T. L. Yang, C. S.
Huang. A phase II trial of docetaxel, capecitabine, and cisplatin as
neoadjuvant chemotherapy for locally advanced breast cancer. Journal of
Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No.
16S, Part I of II (June 1 Supplement), 2005: 861
9. Yen-Shen Lu, Pei-Yen Yeh, Ming Gao, Shuang-En Chuang, Ann-Lii
Cheng: Glucocorticoids (GC) enhance p21 expression and induce G1
phase cell cycle arrest in MCF-7 cells - the possible role of GC receptors
and their co-regulator. AACR Meeting Abstracts, Mar 2004; 2004: 100
10.Yen-Shen Lu, Chiun-Sheng Huang: Phase II Trial Combining Weekly
Doxetaxel with Tegafur/Uracil for Chemo- therapy-Naive Patients with
Locally Advanced or Metastatic Breast Carcinoma. (2005/12) Poster
Session
11.Yen-Shen Lu, Pei-Yen Yeh, Sung-Hsin Kuo, Wen-Ching Chang, Ann-Lii
Cheng.: Expression of glucocorticoids receptor in tumor tissue may affect
the outcome of advanced non-small cell lung cancer patients who received
chemotherapy and concurrent glucocorticoids treatment. AACR Meeting
Abstracts, Apr 2005; 2005: 952 - 953.
12.Yen-Shen Lu, Yoko Kashida, Jui-Hsiang Hung, Chang-Shi Chen,
Yu-Chieh Wang, Ann-Lii Cheng, Ching-Shih Chen.: In Vivo Efficacy of
OSU-HDAC42, a Novel Phenylbutyrate-based Histone Deacetylase
Inhibitor, in Human Hepatocellular Carcinoma Animal Models. AACR
Meeting Abstracts, Apr 2007; 2007: 705
13.Yen-Shen Lu, Pei-Yen Yeh, Chih-Hung Hsu, Sung-Hsin Kuo, An-Chieh
Lee, Ann-Lii Cheng, Differential regulation of cytokine expression
determines the different drug sensitivity between carcinomas and
lymphomas towards mTOR inhibitor AACR Meeting Abstracts, Apr 2008;
2008: 1478
14.Chun-Te Chiang, Yen-Shen Lu, Pei-Yen Yeh, Ling-Chun Yeh, Chih-Hung
Hsu, Sung-Hsin Kuo, Ann-Lii Cheng, RAD001 Sensitizes Gemcitabineand Paclitaxel-induced Cytotoxicity in Non-Hodgkin's Lymphoma Cells
AACR Meeting Abstracts, Apr 2009; 2009: 1837.
15.Ming Gao, Pei-Yen Yeh, Ching-Hung Lin, Yen-Shen Lu, Min-Liang Kuo,
and Ann-Lii Cheng NF- B p50-mediated down-regulation of CRMP-1 is
involved in tumor cell invasiveness in human lung adenocarcinoma cells
AACR Meeting Abstracts, Apr 2008; 2008: 4552.
16.Y. Lu, L. Tseng, M. Hou, C. Lin, H. Li, S. Chen. Treatment patterns and
clinical outcomes of patients with advanced breast cancer after failure of
an anthracycline and a taxane in Taiwan. 2010 ASCO Annual Meeting J
Clin Oncol 28, 2010 (suppl; abstr e11504)
17.C. Lin, C. Huang, Y. Lu, J. Laiu, S. Huang, W. Kuo, W. Kuo, K. Chang, A.
Cheng. Evaluation of estrogen receptor expression as a prognostic factor
for very young women (below 35 years) with breast cancer in Taiwan J
Clin Oncol 27, 2009 (suppl; abstr e22163)
18.Y. Shen, C. Hsu, S. Kuo, Y. Lu, C. Lin, C. Huang, A. Cheng A phase II
study of weekly low-dose paclitaxel plus 24-hour infusion of cisplatin as
first-line chemotherapy for metastatic breast cancer (MBC) Journal of
Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25,
No. 18S (June 20 Supplement), 2007: 1100
19.Jason Chia-Hsien Cheng, Chia-Hung Chou, Yen-Shen Lu, Ipih Hana,
Chan-Hsun Hsu, Ann-Lii Cheng, and Ching-Shih Chen Abstract #3963:
Efficacy of combining a novel histone deacetylase inhibitor with
radiotherapy in human hepatocellular carcinoma through inhibition of DNA
repair AACR Meeting Abstracts, Apr 2009; 2009: 3963.
20.Ming Gao, Pei Yen Yeh, Yen-Shen Lu, Hsiu-Mei Lin, and Ann-Lii Cheng
Abstract #4208: EGFR variant 4 complexes with NF-κB p50 to upregulate
VEGF receptor 2 expression in lung cancer cells. AACR Meeting Abstracts,
Apr 2009; 2009: 4208.
21.Y.H. Kuo, C.H. Lin, W.Y. Shau, T.J. Chen, S.H. Yang, S.M. Huang, A.L. Cheng, Y.S. Lu,
DYNAMICS OF CIRCULATING ENDOTHELIAL CELLS AND ENDOTHELIAL
PROGENITOR CELLS IN BREAST CANCER PATIENTS RECEIVING CYTOTOXIC
CHEMOTHERAPY. Ann Oncol (2010) 21(suppl 8): viii78-viii95
Book：
1. Arrong Sargen, Yen-Shen Lu, Ann-Lii Cheng, Ching-Shih Cheng. Chapter
12; Histone Deacetylase Inhibitors in Cancer Therapy; Cancer Epigenetics
ed 1. Taylor & Francis , 2008,
CURRICULUM VIATE
Yen - Shen Lu, MD., PhD.
盧彥伸醫師
PERSONAL：
Address:
Department of Oncology
National Taiwan University Hospital
#7 Chung-Shan South Road,
Taipei, Taiwan, 100
Tel：886-2-23123456 ext 7009
Fax：886-2-23711174
e-mail：[email protected]
Date of Birth: Nov 11, 1966
Place of Birth: Taipei, Taiwan
Marital Status: Married
EDUCATION：
M.D.
Chinese Medical College of Medicine 1985-1992
Ph.D.
Institute of Clinical Medicine, National Taiwan University College of
Medicine 1998-2006
PROFESSIONAL TRAINING：
1991-1992
Internship：National Taiwan University College of Medicine
1993-1996
Residency：Department of Medicine, National Taiwan University
Hospital
1996-1997
Chief Residency：Department of Oncology, National Taiwan
University Hospital
1997-1999
Fellowship, Department of Oncology, National Taiwan University
Hospital
2005-2006
Clinical fellow and Postdoctoral researcher, College of pharmacy,
and Comprehensive Cancer Center, Ohio State University
HOSPITAL APPOINTMENTS：
1999-2001
Attending doctor, Department of Oncology, En Chu Kong Hospital
2001-present Attending doctor, Department of Oncology, National Taiwan
University Hospital
ACADEMIC APPOINTMENTS：
2007-2008
Adjunct Associate Professor, Department of Internal Medicine,
National Taiwan University College of Medicine
2008-present
Clinical Associate Professor, Department of Internal Medicine,
National Taiwan University College of Medicine
LICENSURE and CENTIFICATION：
Chinese Medical License
#021928（1992）
Chinese Board of Internal Medicine #004509（1997）
Chinese Board of Medical Oncology #870003 (1998 )
Chinese Board of Mammary Medicine #0415 ( 2006 )
MEMBERSHIPS：
Taiwan Society of Internal Medicine
1996 – Present
The Chinese Oncology Society
1998 – Present
The Breast Cancer Society of Taiwan
2004 - Present
American Association of Cancer Research
2001-Present
Awards:
Scholar in Training Award of 92th Annual Meeting of AACR in 2001.
SCI PUBLICATIONS：
46.Po-Han Lin; Chang-Fang Chiu; Yen-Shen Lu. Cisplatin as an active
treatment in zoledronate-refractory hypercalcemia. Ann Oncol. 2011 Apr 2
[Epub ahead of print] PMID:21460375
47.Lack of compensatory pAKT activation and eIF4E phosphorylation of
lymphoma cells towards mTOR inhibitor, RAD001. Kuo SH, Hsu CH, Chen
LT, Lu YS, Lin CH, Yeh PY, Jeng HJ, Gao M, Yeh KH, Cheng AL Eur J
Cancer. 2011 Feb 17.
48.The Association of Infrared Imaging Findings of the Breast with Hormone
Receptor and Human Epidermal Growth Factor Receptor 2 Status of
Breast Cancer. Wang J, Shih TT, Yen RF, Lu YS, Chen CY, Mao TL, Lin
CH, Kuo WH, Tsai YS, Chang KJ, Chien KL. Acad Radiol. 2010 Dec 1
49.Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant
chemotherapy for locally advanced breast cancer Yen-Shen Lu, Dar-Ren
Chen, Ling-Min Tseng, Dah-Cherng Yeh, Shou-Tung Chen, Chia-Ming
Hsieh, Hwei-Chung Wang, Hsien-Tang Yeh, Sung-Hsin Kuo, Chiun-Sheng
Huang. Cancer Chemotherapy and Pharmacology. 2010 In press
50.Combinations of mTORC1 inhibitor RAD001 with gemcitabine and
paclitaxel for treating non-Hodgkin lymphoma Chun-Te Chiang, Pei-Yen
Yeh, Ming Gao, Chun-Wei Chen, Ling-Chun Yeh, Wen-Chi Feng,
Sung-Hsin Kuo, Chih-Hung Hsu, Yen-Shen Lu* and Ann-Lii Cheng,
Cancer Letter, 2010, 2010 Dec 8;298(2):195-203. (*corresponding author)
51.The prevalence and assessment of ErbB2-positive breast cancer in Asia:
A literature survey. Yew Oo Tan, Sehwan Han, Yen-Shen Lu, Cheng-Har
Yip, Patrapim Sunpaweravong, Joon Jeong, Priscilla B. Caguioa, Shyam
Aggarwal, Ee Min Yeoh, BSc, and Hanlim Moon. Cancer, 2010 Dec
1;116(23):5348-57.
52.Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and
leucovorin as effective palliative chemotherapy for breast cancer patients
with acute disseminated intravascular coagulation, Po-Han Lin, Yen-Shen
Lu, Ching-Hung Lin, Dwan-Ying Chang, Chiun-Shen Huang, Ann-Lii
Cheng,Kun-Huei Yeh Anticancer Research 2010 Jul;30(7):3087-91.
53.Management of ErbB2-positive breast cancer – insights from preclinical
and clinical studies with lapatinib, Charles Vogel, Arlene Chan, Brunilde
Gril, Sung-Bae Kim, Junichi Kurebayashi, Li Liu, Yen-Shen Lu, Hanlim
Moon Jap. J Clin. Oncol. 2010 Nov;40(11):999-1013
54.Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast
Cancer Patients Treated with Paclitaxel and Cisplatin. Shao YY, Kuo KT,
Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ,
Lin CH, Cheng AL. Jpn J Clin Oncol. 2010 Apr;40(4):286-93
55.Unique features of breast cancer in Asian women-Breast cancer in Taiwan
as an example. Huang CS, Lin CH, Lu YS, Shen CY. J Steroid Biochem
Mol Biol. 2010 Feb 28;118(4-5):300-3..
56.Fractionated evaluation of immunohistochemical hormone receptor
expression enhances prognostic prediction in breast cancer patients
treated with tamoxifen as adjuvant therapy. Lin CH, Lien HC, Hu FC, Lu
YS, Kuo SH, Wu LC, You SL, Cheng AL, Chang KJ, Huang CS. J Zhejiang
Univ Sci B. 2010 Jan;11(1):1-9.
57.Management of HER2-positive breast cancer in Asia: consensus
statement from the Asian Oncology Summit. Nan Soon Wong, Benjamin O
Anderson, Kei Siong Khoo, Peng Tiam Ang, Cheng Har Yip,Yen-Shen Lu,
Narind Voravud, Zhi-Ming Shao, Kathleen I Pritchard. Lancet Oncol.
2009 Nov;10(11):1077-85.
58.O(6)-Methylguanine-DNA methyltransferase expression and prognostic
value in brain metastases of lung cancers. Wu PF, Kuo KT, Kuo LT, Lin
YT, Lee WC, Lu YS, Yang CH, Wu RM, Tu YK, Tasi JC, Tseng HM, Tseng
SH, Cheng AL, Lin CH. Lung Cancer. 2009 Sep 7
59.Locoregional Therapy Improves Survival for Metastatic Breast Cancer
Patients? Benefit Remains Questionable! Chang DY, Lin CH, Lu YS.
J Clin Oncol. 2009 Nov 1;27(31):e179;
60.Induction of Bim Expression Contributes to the Antitumor Synergy
Between Sorafenib and Mitogen-Activated Protein Kinase/Extracellular
Signal-Regulated Kinase Kinase Inhibitor CI-1040 in Hepatocellular
Carcinoma. Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang
DS, Lu YS, Hsu C, Cheng AL.
Clin Cancer Res. 2009 Sep 8.
15(18):5820-8.
61.Molecular Subtypes of Breast Cancer Emerging in Young Women in
Taiwan: Evidence for More than Just Westernization as a Reason for the
Disease in Asia Ching-Hung Lin, Jau-Yu Liau, Yen-Shen Lu, Chiun-Sheng
Huang, Wei-Chung Lee, Kuan-Ting Kuo, Ying-Chun Shen, Sung-Hsin Kuo,
Chieh Lan, Jacqueline Ming Liu, Wun-Hon Kuo, King-Jen Chang, and
Ann-Lii Cheng,
Cancer Epidemiology, Biomarkers & Prevention. 2009
Jun;18(6):1807-14.
62.Bortezomib overcomes TRAIL resistance in hepatocellular carcinoma cells
in part through the inhibition of PI3K/Akt pathway Kuen-Feng Chen,
Pei-Yen Yeh, Chiun Hsu , Chih-Hung Hsu, Yen-Shen Lu, Hsing-Pang
Hsieh, Pei-Jer Chen, Ann-Lii Cheng.
J. Biol Chem 2009 April
24;284(17):11121-33.
63. OSU-03012, a novel celecoxib derivative, induces reactive oxygen
species-related autophagy in hepatocellular carcinoma.Gao M, Yeh PY, Lu
YS, Hsu CH, Chen KF, Lee WC, Feng WC, Chen CS, Kuo ML, Cheng AL. .
Cancer Res 2008 Nov 15;68(22):9348-57.
64.NF-kappaB p50 promotes tumor cell invasion through negative regulation
of invasion suppressor gene CRMP-1 in human lung adenocarcinoma
cells. Gao M, Yeh PY, Lu YS, Chang WC, Kuo ML, Cheng AL. Biochem
Biophys Res Commun. 2008 Nov 14;376(2):283-7.
65.Down-regulation of phospho-Akt is a major molecular determinant of
bortezomib-induced apoptosis in hepatocellular carcinoma cells. Chen KF,
Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL Cancer Res. 2008 Aug
15;68(16):6698-707.
66.Dose variation and regimen modification of adjuvant chemotherapy in daily
practice affect survival of stage I-II and operable stage III Taiwanese
breast cancer patients. Kuo SH, Lien HC, You SL, Lu YS, Lin CH, Chen
TZ, Huang CS, Breast. 2008 Dec;17(6):646-53. Epub 2008 Jul 1
67.The CYP19 TTTA Repeat Polymorphism Is Related to the Prognosis of
Premenopausal Stage I-II and Operable Stage III Breast Cancers, Huang
CS, Kuo SH, Lien HC, Yang SY, You SL, Shen CY, Lin CH, Lu YS, Chang
KJ. Oncologist. 2008;13:751-60.
68.Differential expression of glucocorticoid receptor in carcinomas of the
human digestive system, H-C Lien, Y-S Lu, C-T Shun, Y-T Yao, W-C
Chang1 & A-L Cheng Histopathology 2008 Feb;46(4):1119-30
69.FTY720 Induces Apoptosis in Hepatocellular Carcinoma Cells through
Activation of Protein Kinase C Delta Signaling. Jui-Hsiang Hung,
Yen-Shen Lu, Yu-Chieh Wang, Yi-Hui Ma, Da-Sheng Wang, Samuel K.
Kulp, Natarajan Muthusamy, John C Byrd, Ann-Lii Cheng, and Ching-Shih
Chen Cancer Research, 68:1204-1212, 2008.
70.Efficacy of OSU-HDAC42, a Novel Histone Deacetylase Inhibitor, in
Murine Models of Hepatocellular Carcinoma Yen-Shen Lu, Yoko Kashida,
Samuel K. Kulp, Yu-Chieh Wang, Jui-Hsiang Hung, Monica Tang,
Zhong-Zhe Lin, Te-Jung Chen, Ann-Lii Cheng, and Ching-Shih Chen.
Hepatology, 2007 Oct;46(4):1119-30.
71.Pneumatosis coli after etoposide chemotherapy for breast cancer. Shih IL,
Lu YS, Wang HP, Liu KL. J Clin Oncol. 2007 Apr 20;25(12):1623-5.
72.Histone deacetylase inhibitors sensitize prostate cancer cells to agents
that produce DNA double-strand breaks by targeting Ku70 acetylation.
Chen CS, Wang YC, Yang HC, Huang PH, Kulp SK, Yang CC, Lu YS,
Matsuyama S, Chen CY, Chen CS. Cancer Res. 2007 Jun
1;67(11):5318-27.
73.A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus
leucovorin in patients with chemotherapy-pretreated metastatic breast
cancer. Lin CC, Cheng AL, Hsu CH, Lu YS, Hsu C, Yeh KH, Wu CY,
Huang CS, Yang CH. Anticancer Res. 2007 ;27(1B):641-5.
74.Differential expression of glucocorticoid receptor in human breast tissues
and related neoplasms. Lien HC, Lu YS, Cheng AL, Chang WC, Jeng YM,
Kuo YH, Huang CS, Chang KJ, Yao YT. J Pathol. 2006 Jul;209(3):317-27.
75.Glucocorticoid receptor expression in advanced non-small cell lung cancer:
clinicopathological correlation and in vitro effect of glucocorticoid on cell
growth and chemosensitivity Lu YS, Lien HC, Yeh PY, Kuo SH, Chang
WC, Kuo ML, Cheng AL. Lung Cancer. 2006 Sep;53(3):303-10.
76.Phase I study of biweekly gemcitabine followed by oxaliplatin and
simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic
cancer. Ch'ang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin
JT, Wang HP, Shiah HS, Liu TW, Chang JY, Whang-Peng J, Chen LT. J
Gastroenterol Hepatol. 2006 May;21(5):874-9.
77.Glucocorticoids enhance cytotoxicity of cisplatin via suppression of
NF-{kappa}B activation in the glucocorticoid receptor-rich human cervical
carcinoma cell line SiHa. Lu YS, Yeh PY, Chuang SE, Gao M, Kuo ML,
Cheng AL. J Endocrinol. 2006 Feb;188(2):311-9.
78.Effects of glucocorticoids on the growth and chemosensitivity of carcinoma
cells are heterogeneous and require high concentration of functional
glucocorticoid receptors. Lu YS, Lien HC, Yeh PY, Yeh KH, Kuo ML, Kuo
SH, Cheng AL. World J Gastroenterol. 2005 Oct 28;11(40):6373-80.
79.Long-term hepatic consequences of chemotherapy-related HBV
reactivation in lymphoma patients. Su WP, Wen CC, Hsiung CA, Su IJ,
Cheng AL, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu C, Hsu CH, Lu
YS, Tien HF, Chao TY, Chen LT, Whang-Peng J, Chen PJ. World J
Gastroenterol. 2005 Sep 14;11(34):5283-8.
80.Phase II Study of Weekly Paclitaxel and 24-Hour Infusion of High-Dose
5-Fluorouracil and Leucovorin in the Treatment of Recurrent or Metastatic
Gastric Cancer. Kun-Huei Yeh, Yen-Shen Lu, Chih-Hung Hsu, Jing-Fang
Lin, Chiun Hsu, Sung-Hsin Kuo, Shiou-Jr Li, Ann-Lii Cheng. Oncology
2005 Oncology. 2005;69(1):88-95.
81.Phase II Study of Weekly Vinorelbine and 24-hour Infusion of High-dose
5-Fluorouracil Plus Leucovorin as First-line Treatment of Advanced Breast
Cancer KH Yeh, YS Lu, CH Hsu, JF Lin, HJ Chao, TC Huang, CY Chung,
CS Chang, CH Yang, AL Cheng British Journal of Cancer . 2005
92:1013-1018
82.Angiogenic response of locally advanced breast cancer to neoadjuvant
chemotherapy evaluated with parametric histogram from dynamic
contrast-enhanced MRI. Yeun-Chung Chang, Chiun-Sheng Huang, Yi-Jui
Liu, Jyh-Horng Chen, Yen-Shen Lu, Wen-Yih I Tseng Phys. Med. Biol. 49
(2004)3593-3602 2004
83.Phase II study of combination doxorubicin, interferon-alpha, and high-dose
tamoxifen treatment for advanced hepatocellular carcinoma. Lu YS. Hsu C.
Li CC. Kuo SH. Yeh KH. Yang CH. Hsu CH. Wu CY. Cheng AL
Hepato-Gastroenterology. 51(57):815-9, 2004
84.Recent advances in the management of primary breast cancers. Lu YS,
Kuo SH, Huang CS J Formos Med Assoc. 103(8):579-98.2004
85.Weekly gemcitabine plus 24-h infusion of high-dose
5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of
the biliary tract. Hsu C. Shen YC. Yang CH. Yeh KH. Lu YS. Hsu CH. Liu
HT. Li CC. Chen JS. Wu CY. Cheng AL British Journal of Cancer.
90(9):1715-9,2004
86.High-dose tamoxifen modulates drug resistance to doxorubicin,
dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma. Yeh KH.
Lu YS. Hsiao CH. Cheng AL. Anticancer Research. 23(6D):5133-7, 2003
87.A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of
high-dose 5-f;uorouracil and leucovorin (MP-HDFL) in patients with
metastatic and recurrent esophageal cancer – improving toxicity profile by
infusional schedule and double biochemical modulation of 5-fluorouracil.
CH Hsu, AL Cheng, C Hsu, CH Yang, YS Lu, CC Lin, CF Bu, KH Yeh.
Anticancer Research. 22: 3621-28, 2002.
88.Phase II trial combining paclitaxel with 24-hour infusion cisplatin for
chemotherapy-naïve patients with locally advanced or metastatic breast
cancer. C, Hsu, CS Huang, TY Chao, YS Lu. CF Bu, MM, Chen, AL
Cheng. Cancer 95(10) 2044-50, 2002.
89.Basal levels and patterns of anticancer drug-induced activation of NF-kB,
and its attenuation by tamoxifen, dexamethasone, and curcumin in
carcinoma cells. S.E. Chung, P.Y. Yeh, Y.S. Lu, G.M. Lai, C.M. Liao, M.
Gao, A.L. Cheng. Biochemical Pharmacology. 63(9):1709-16, 2002.
90.Chen HS. Yen TS. Lu YS. Yang JC. Ko YL. Transient 'milky urine' after
cardiac catheterization: another unreported cause of non-parasitic chyluria
[letter]. Nephron. 72(2):367-8, 1996.
Conference paper：
22.C. Hsu, Y.-C. Shen, C.-H. Yang, K.-H. Yeh, Y.-S. Lu, C.-C. Li, C.-Y. Wu,
A.-L. Cheng Phase II study of weekly gemcitabine plus 24-hour infusion of
high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic
carcinoma of the biliary tract Proc Am Soc Clin Oncol 22: 2003 (abstr
1322)
23.K. H. Yeh, W. Lu, Y. F. Ho, Y. Lu, M. Y. Liu, R. R. Chen, A. L. Cheng A
phase I and pharmacokinetic study of weekly 48-hour infusion of
high-dose 5-fluorouracil and folinic acid in patients with
recurrent/metastatic colorectal cancer 2004 Gastrointestinal Cancer
Synposium abstract 261
24.KH Yeh, YS Lu, CH Hsu, C Hsu, H J Chao, CH Hsiao, SH Kuo, JC Lin, CH
Yang, AL Cheng A phase II study of weekly vinorelbine and 24-hour
infusion of high-dose 5-fluorouracil/leucovorin (VNB-HDFL) in the first-line
treatment of advanced breast cancer Proc Am Soc Clin Oncol 21: 2002
(abstr 2006)
25.K. Yeh, C. Hsu, Y. Lu, C. Hsu, S. Kuo, C. Huang, Y. Shen, C. Hsiao, C.
Yang, A. Cheng. Phase II study of sequential non-cross-resistant
chemotherapy using weekly 24-hour infusion of cisplatin, high-dose
5-fluorouracil and leucovorin (P-HDFL) followed by weekly docetaxel and
irinotecan (DI) for recurrent or metastatic gastric cancer: an interim
analysis Journal of Clinical Oncology, 2006 ASCO Annual Meeting
Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 14063
26.K.-H. Yeh, C.-H. Hsu, J.-F. Lin, Y.-S. Lu, H.-T. Li, C.-L. Huang, C.-H.
Hsiao, A.-L. Cheng. Prolonged survival in a pilot study of sequential
non-cross-resistant chemotherapy using weekly 24-hour infusion of
cisplatin, high-dose 5-fluorouracil and leucovorin (P-HDFL) followed by
weekly docetaxel and irinotecan (DI) for recurrent or metastatic gastric
cancer Proc Am Soc Clin Oncol 22: 2003 (abstr 1229)
27.C.-H. Hsu, K.-H. Yeh, C.-C. Lin, Z.-Z. Lin, C. Hsu, Y.-S. Lu, C.-F. Bu, A.-L.
Cheng. Multi-fractionation of paclitaxel and cisplatin by twice weekly
schedule, plus weekly 24-hour infusion of high-dose 5-fluorouracil and
leucovorin (twice weekly TP-HDFL) in the treatment of metastatic or
recurrent esophageal cancer. Proc Am Soc Clin Oncol 22: 2003 (abstr
1336)
28.Chih-Hung Hsu, Kun-Huei Yeh, Chiun Hsu, Chih-Hsin Yang, Yen-Shen Lu,
Chia-Chi Lin, Ching-Fang Bu, Ann-Lii Cheng. Phase II Clinical Trial of
Methotrexate, Cisplatin, and 24-Hour Infusion of High-Dose 5-Fluororuacil
and Leucovorin (MP-HDFL) for the Treatment of Metastatic or Recurrent
Esophageal Cancer Proc Am Soc Clin Oncol 20: 2001 (abstr 2299)
29.Y. S. Lu, S. H. Kuo, W. P. Su, C. H. Yang, C. Hsu, T. L. Yang, C. S.
Huang. A phase II trial of docetaxel, capecitabine, and cisplatin as
neoadjuvant chemotherapy for locally advanced breast cancer. Journal of
Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No.
16S, Part I of II (June 1 Supplement), 2005: 861
30.Yen-Shen Lu, Pei-Yen Yeh, Ming Gao, Shuang-En Chuang, Ann-Lii
Cheng: Glucocorticoids (GC) enhance p21 expression and induce G1
phase cell cycle arrest in MCF-7 cells - the possible role of GC receptors
and their co-regulator. AACR Meeting Abstracts, Mar 2004; 2004: 100
31.Yen-Shen Lu, Chiun-Sheng Huang: Phase II Trial Combining Weekly
Doxetaxel with Tegafur/Uracil for Chemo- therapy-Naive Patients with
Locally Advanced or Metastatic Breast Carcinoma. (2005/12) Poster
Session
32.Yen-Shen Lu, Pei-Yen Yeh, Sung-Hsin Kuo, Wen-Ching Chang, Ann-Lii
Cheng.: Expression of glucocorticoids receptor in tumor tissue may affect
the outcome of advanced non-small cell lung cancer patients who received
chemotherapy and concurrent glucocorticoids treatment. AACR Meeting
Abstracts, Apr 2005; 2005: 952 - 953.
33.Yen-Shen Lu, Yoko Kashida, Jui-Hsiang Hung, Chang-Shi Chen,
Yu-Chieh Wang, Ann-Lii Cheng, Ching-Shih Chen.: In Vivo Efficacy of
OSU-HDAC42, a Novel Phenylbutyrate-based Histone Deacetylase
Inhibitor, in Human Hepatocellular Carcinoma Animal Models. AACR
Meeting Abstracts, Apr 2007; 2007: 705
34.Yen-Shen Lu, Pei-Yen Yeh, Chih-Hung Hsu, Sung-Hsin Kuo, An-Chieh
Lee, Ann-Lii Cheng, Differential regulation of cytokine expression
determines the different drug sensitivity between carcinomas and
lymphomas towards mTOR inhibitor AACR Meeting Abstracts, Apr 2008;
2008: 1478
35.Chun-Te Chiang, Yen-Shen Lu, Pei-Yen Yeh, Ling-Chun Yeh, Chih-Hung
Hsu, Sung-Hsin Kuo, Ann-Lii Cheng, RAD001 Sensitizes Gemcitabineand Paclitaxel-induced Cytotoxicity in Non-Hodgkin's Lymphoma Cells
AACR Meeting Abstracts, Apr 2009; 2009: 1837.
36.Ming Gao, Pei-Yen Yeh, Ching-Hung Lin, Yen-Shen Lu, Min-Liang Kuo,
and Ann-Lii Cheng NF- B p50-mediated down-regulation of CRMP-1 is
involved in tumor cell invasiveness in human lung adenocarcinoma cells
AACR Meeting Abstracts, Apr 2008; 2008: 4552.
37.Y. Lu, L. Tseng, M. Hou, C. Lin, H. Li, S. Chen. Treatment patterns and
clinical outcomes of patients with advanced breast cancer after failure of
an anthracycline and a taxane in Taiwan. 2010 ASCO Annual Meeting J
Clin Oncol 28, 2010 (suppl; abstr e11504)
38.C. Lin, C. Huang, Y. Lu, J. Laiu, S. Huang, W. Kuo, W. Kuo, K. Chang, A.
Cheng. Evaluation of estrogen receptor expression as a prognostic factor
for very young women (below 35 years) with breast cancer in Taiwan J
Clin Oncol 27, 2009 (suppl; abstr e22163)
39.Y. Shen, C. Hsu, S. Kuo, Y. Lu, C. Lin, C. Huang, A. Cheng A phase II
study of weekly low-dose paclitaxel plus 24-hour infusion of cisplatin as
first-line chemotherapy for metastatic breast cancer (MBC) Journal of
Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25,
No. 18S (June 20 Supplement), 2007: 1100
40.Jason Chia-Hsien Cheng, Chia-Hung Chou, Yen-Shen Lu, Ipih Hana,
Chan-Hsun Hsu, Ann-Lii Cheng, and Ching-Shih Chen Abstract #3963:
Efficacy of combining a novel histone deacetylase inhibitor with
radiotherapy in human hepatocellular carcinoma through inhibition of DNA
repair AACR Meeting Abstracts, Apr 2009; 2009: 3963.
41.Ming Gao, Pei Yen Yeh, Yen-Shen Lu, Hsiu-Mei Lin, and Ann-Lii Cheng
Abstract #4208: EGFR variant 4 complexes with NF-κB p50 to upregulate
VEGF receptor 2 expression in lung cancer cells. AACR Meeting Abstracts,
Apr 2009; 2009: 4208.
42.Y.H. Kuo, C.H. Lin, W.Y. Shau, T.J. Chen, S.H. Yang, S.M. Huang, A.L. Cheng, Y.S. Lu,
DYNAMICS OF CIRCULATING ENDOTHELIAL CELLS AND ENDOTHELIAL
PROGENITOR CELLS IN BREAST CANCER PATIENTS RECEIVING CYTOTOXIC
CHEMOTHERAPY. Ann Oncol (2010) 21(suppl 8): viii78-viii95
Book：
1. Arrong Sargen, Yen-Shen Lu, Ann-Lii Cheng, Ching-Shih Cheng. Chapter
12; Histone Deacetylase Inhibitors in Cancer Therapy; Cancer Epigenetics
ed 1. Taylor & Francis , 2008,